Literature DB >> 21575129

Genome scan of clot lysis time and its association with thrombosis in a protein C-deficient kindred.

M E Meltzer1, S J Hasstedt, C Y Vossen, P W Callas, Ph G DE Groot, F R Rosendaal, T Lisman, E G Bovill.   

Abstract

BACKGROUND: Previously, we found increased clot-lysis time (CLT), as measured with a plasma-based assay, to increase the risk of venous thrombosis in two population-based case-control studies. The genes influencing CLT are as yet unknown. PATIENTS/
METHODS: We tested CLT as risk factor for venous thrombosis in Kindred Vermont II (n = 346), a pedigree suffering from a high thrombosis risk, partially attributable to a type I protein C deficiency. Furthermore, we tested for quantitative trait loci (QTLs) for CLT, using variance component linkage analysis.
RESULTS: Protein C-deficient family members had shorter CLTs than non-deficient members (median CLT 67 min vs. 75 min). One standard deviation increase in CLT increased the risk of venous thrombosis 2.4-fold in non-deficient family members. Protein C deficiency without elevated CLT increased the risk 6.9-fold. Combining both risk factors yielded a 27.8-fold increased risk. The heritability of CLT was 42-52%. We found suggestive evidence of linkage on chromosome 11 (62 cM), partly explained by the prothrombin 20210A mutation, and on chromosome 13 (52 cM). Thrombin-activatable fibrinolysis inhibitor genotypes did not explain the variation in CLT.
CONCLUSION: Hypofibrinolysis appears to increase thrombosis risk in this family, especially in combination with protein C deficiency. Protein C deficiency is associated with short CLT. CLT is partly genetically regulated. Suggestive QTLs were found on chromosomes 11 and 13.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21575129      PMCID: PMC3138551          DOI: 10.1111/j.1538-7836.2011.04343.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  35 in total

1.  Adjusting for covariates in variance components QTL linkage analysis.

Authors:  Maurice Zeegers; Fruhling Rijsdijk; Pak Sham
Journal:  Behav Genet       Date:  2004-03       Impact factor: 2.805

2.  Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.

Authors:  T Lisman; F W Leebeek; L O Mosnier; B N Bouma; J C Meijers; H L Janssen; H K Nieuwenhuis; P G De Groot
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  The G20210A prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein C deficient kindred.

Authors:  E G Bovill; S J Hasstedt; P W Callas; J E Valliere; B T Scott; K A Bauer; G L Long
Journal:  Thromb Haemost       Date:  2000-03       Impact factor: 5.249

4.  Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.

Authors:  Mirjam E Meltzer; Ton Lisman; Philip G de Groot; Joost C M Meijers; Saskia le Cessie; Carine J M Doggen; Frits R Rosendaal
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

5.  A general model for the genetic analysis of pedigree data.

Authors:  R C Elston; J Stewart
Journal:  Hum Hered       Date:  1971       Impact factor: 0.444

6.  Genome scan of venous thrombosis in a pedigree with protein C deficiency.

Authors:  S J Hasstedt; B T Scott; P W Callas; C Y Vossen; F R Rosendaal; G L Long; E G Bovill
Journal:  J Thromb Haemost       Date:  2004-06       Impact factor: 5.824

7.  Inter-relation of coagulation factors and d-dimer levels in healthy individuals.

Authors:  A Van Hylckama Vlieg; P W Callas; M Cushman; R M Bertina; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2003-03       Impact factor: 5.824

8.  Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism.

Authors:  Mario Colucci; Bianca M Binetti; Armando Tripodi; Veena Chantarangkul; Nicola Semeraro
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

9.  Plasma inhibitors of the components of the fibrinolytic pathway in man.

Authors:  A D Schreiber; A P Kaplan; K F Austen
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

10.  Vascular endothelial growth factor, epidermal growth factor and fibroblast growth factor-4 and -10 stimulate trophoblast plasminogen activator system and metalloproteinase-9.

Authors:  E Y Anteby; C Greenfield; S Natanson-Yaron; D Goldman-Wohl; Y Hamani; V Khudyak; I Ariel; S Yagel
Journal:  Mol Hum Reprod       Date:  2004-03-02       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.